Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.

International journal of surgery (London, England) - 1 Aug 2024

Sun Yuming, Liu Yongjia, Dian Yating, Zeng Furong, Deng Guangtong, Lei Shaorong

Abstract excerpt

BACKGROUND: Glucagon-like peptide-1 receptor (GLP1R) agonists have been approved by Food and Drug Administration for management of obesity. However, the causal relationship of GLP1R agonists (GLP1RA) with cancers still unclear. METHODS: The available cis-eQTLs for drugs target genes (GLP1R) were used as proxies for exposure to GLP1RA. Mendelian randomizations (MR) were performed to reveal the association of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 2
Share to Diabetes Treatment and Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucagon-Like Peptide-1 Receptor

Share to Hypoglycemic Agents

Share to Mendelian Randomization Analysis

Share to Neoplasms

Share to Polymorphism, Single Nucleotide

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 38701500
DOI: 10.1097/JS9.0000000000001514
PMCID: PMC11325911

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.PMID 38701500Read ↗

Association of glucose-lowering drug target and risk of gastrointestinal cancer: a mendelian randomization studySemantic proximity Read ↗

Genetically-proxied anti-diabetic drug target perturbation and risk of cancer: a Mendelian randomization analysisSemantic proximity Read ↗

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.Semantic proximity Read ↗

Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomizationSemantic proximity Read ↗

Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.Semantic proximity Read ↗

Evaluating the causal role of LEPR signaling in 16 cancers: A drug-target Mendelian randomization study.Semantic proximity Read ↗

Metformin treatment and reduction of gastrointestinal cancer risk: A 2-sample Mendelian randomization study.Semantic proximity Read ↗

Genetic association of glycemic traits and antihyperglycemic agent target genes with the risk of lung cancer: A Mendelian randomization study.Semantic proximity Read ↗

Systematic review of Mendelian randomization studies on risk of cancer.Semantic proximity Read ↗

Causal association of childhood obesity with cancer risk in adulthood: A Mendelian randomization study.Semantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.